• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Psychemedics Corporation (Amendment)

    4/21/22 3:03:48 PM ET
    $PMD
    Medical Specialities
    Health Care
    Get the next $PMD alert in real time by email
    SC 13D/A 1 sc13da408568007_04212022.htm AMENDMENT NO. 4 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 4)1

    Psychemedics Corp

    (Name of Issuer)

    Common Stock, par value $0.005 per share

    (Title of Class of Securities)

    744375205

    (CUSIP Number)

    PETER H. KAMIN

    2720 Donald Ross Road, #311

    Palm Beach Gardens, FL 33410

     

    STEVE WOLOSKY, ESQ.

    ANDREW FREEDMAN, ESQ.

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    April 19, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 744375205

      1   NAME OF REPORTING PERSON  
             
            PETER H. KAMIN  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            PF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES OF AMERICA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         624,737 (1)  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              624,737 (1)  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            624,737 (1)  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            11.2%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    (1) Includes 218,728 shares of Common Stock held by the Peter H. Kamin Revocable Trust dated February 2003, of which Peter H. Kamin (“Kamin”) is the sole trustee, 146,998 shares of Common Stock held by the Peter H. Kamin Childrens Trust dated March 1997 of which Kamin is the trustee, and 44,980 shares of Common Stock held by 3K Limited Partnership, of which Kamin is the General Partner.

    2

    CUSIP No. 744375205

    The following constitutes Amendment No. 4 to the Schedule 13D filed by the undersigned (“Amendment No. 4”). This Amendment No. 4 amends the Schedule 13D as specifically set forth herein.

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and restated to read as follows:

    All of the Shares held by the Reporting Person to which this Statement relates were purchased using the personal funds of the Reporting Person in open market purchases. The aggregate amount of funds used for the purchase of the securities held by the Reporting Person reported herein was approximately $4,294,068 excluding commissions.

    Item 5.Interest in Securities of the Issuer.

    Items 5(a) and (c) are hereby amended and restated to read as follows:

    (a)       The aggregate percentage of Shares reported owned by the Reporting Person is based upon 5,590,656 Shares outstanding as of March 24, 2022, which is the total number of Shares outstanding as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2022.

    As of the close of business on the date hereof, the Reporting Person may be deemed to beneficially own the 624,737 Shares, constituting approximately 11.2% of the Shares outstanding.

    (c)       Except as set forth on Schedule A hereto, the Reporting Person has not entered into any transactions in the Common Stock during the past sixty days.

    3

    CUSIP No. 744375205

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: April 21, 2022

     

    /s/ Peter H. Kamin

      Peter H. Kamin

     

    4

    CUSIP No. 744375205

    SCHEDULE A

    Transactions in the Securities of the Issuer During the Past Sixty Days

    Date Security Amount of Shs. Bought/(Sold) Approx. price ($) per Share

     

    PETER H. KAMIN

    02/24/2022 Common Stock 3,000 6.58
    02/28/2022 Common Stock 600 6.80
    03/02/2022 Common Stock 160 6.90
    03/07/2022 Common Stock 2,200 6.51
    03/16/2022 Common Stock 25,657 6.51
    03/30/2022 Common Stock 7,814 6.88
    03/31/2022 Common Stock 4,589 6.92
    04/07/2022 Common Stock 3,000 6.68
    04/08/2022 Common Stock 4,000 6.79
    04/19/2022 Common Stock 27,485 6.52
    04/20/2022 Common Stock 15,658 6.72

     

    Get the next $PMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMD
    SEC Filings

    View All

    SEC Form 15-12G filed by Psychemedics Corporation

    15-12G - PSYCHEMEDICS CORP (0000806517) (Filer)

    1/2/25 4:10:54 PM ET
    $PMD
    Medical Specialities
    Health Care

    SEC Form 25 filed by Psychemedics Corporation

    25 - PSYCHEMEDICS CORP (0000806517) (Filer)

    12/13/24 8:00:57 AM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13E3/A filed by Psychemedics Corporation

    SC 13E3/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/10/24 4:46:00 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 8:41:51 PM ET
    $PMD
    Medical Specialities
    Health Care

    Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 5:15:34 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psychemedics Releases 2025 Workforce Insights Report

    DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industry, analyzing hundreds of thousands of samples collected in 2024 across a wide range of sectors, including transportation, manufacturing, healthcare, government, and more. The report reveals critical workforce trends and emerging threats empl

    6/16/25 9:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights

    DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate's or employee's test results fall within a range of positive reports collected over the past 12 months. By segmenting results into four quartiles – Lower, Median, Upper, and Highest – this advanced reporting provides real-time context and bench

    3/3/25 9:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Announces Reverse and Forward Stock Split

    DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) (the "Company"), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the "Reverse Stock Split") followed immediately by a 5,000-for-1 forward stock split of its common stock (the "Forward Stock Split," and together with the Reverse Stock Split, the "Stock Split"), to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 202

    12/2/24 8:10:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 8:41:51 PM ET
    $PMD
    Medical Specialities
    Health Care

    Director Kamin Peter bought $3,312,823 worth of shares (1,409,712 units at $2.35) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/5/24 6:05:08 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Leadership Updates

    Live Leadership Updates

    View All

    Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

    ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

    11/27/23 9:00:00 AM ET
    $NBSE
    $PMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Psychemedics Corporation Reports Third Quarter 2023 Financial Results

    ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company's revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year. The Company has initiated a series of restructuring changes that will align costs with current revenue trends. Res

    11/9/23 5:00:59 PM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

    ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to her new position. Her appointment marks a significant milestone for Psychemedics Corporation as it continues to expand its presence in the rapidly evolving field of substance abuse testing. "We are

    9/21/23 5:00:00 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Financials

    Live finance-specific insights

    View All

    Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

    ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl. Complemented by the detection of cocaine, opioids, PCP, and amphetamines, the advanced panel is a leap forward in drug screening technology. As we grapple with an ongoing labor shortage and with marijuana's legal landscape evolving in 49 states, it's clear that the time for

    10/27/23 11:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Reports Second Quarter 2023 Financial Results

    ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company's revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,000) or $(0.06) per diluted share, for the comparable period last year. In the second quarter, the labor shortage continued to have an adverse impact on our clients' use of hair testing in hirin

    8/11/23 5:10:31 PM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend

    ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023. The Company's revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last ye

    5/9/23 5:30:00 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/12/24 5:15:40 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

    SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/6/24 9:18:20 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/5/24 6:04:48 PM ET
    $PMD
    Medical Specialities
    Health Care